CAMBRIDGE, MA – Developing oral care products to prevent and treat oral diseases requires model systems to test the potential therapies before applying them to humans. However, the ability of current models to accurately reflect human oral physiology or predict the effects of therapies on the human disease state is limited, and can be a rate limiting stage of the development process. Colgate-Palmolive is working with Draper to create an advanced gum tissue model that improves the predictive power of the testing to support the development of improved oral care products.
“Draper engineers have deep expertise in building complex, 3D microfluidic structures to recreate a microenvironment similar to what cells experience in the human body. Colgate-Palmolive scientists are experts in understanding human oral physiology. We are partnering with Colgate scientists to develop an advanced platform that recreates the human oral physiology in an accurate, reproducible, cost-effective and predictive format,” according to Tara Clark, vice president of commercial solutions, Draper.
Draper’s human organ systems (HOS) technology can mimic the functions of human organs and tissues in microscale form to test the effectiveness and safety of therapies. Draper’s HOS consists of multiple organ types in a high-throughput format. The HOS models can be applied beyond consumer products to test drugs and biologics. Using cells obtained from cross-sections of patient populations allows comparative testing to identify personalized therapies.
This oral HOS provides a sophisticated system, which recreates human oral tissue in well-defined conditions to better mimic physiology and predict effects on humans, thereby allowing for faster development of product designed to prevent and cure oral diseases.
By applying multiple engineering disciplines to this systems challenge, Draper’s HOS provides sensors that enable lab scientists to access real-time, objective data. Colgate-Palmolive’s scientists and Draper’s engineers then can work side-by-side to generate data to characterize the potential of their new oral care products. The resulting accurate predictions of the effects of therapies on humans reduce the cost and time spent both in the lab and during the clinical testing.
The oral HOS will allow Colgate-Palmolive to collect higher-quality data more efficiently to better predict how its products improve the health of the user. The goal is to better model the oral tissue to accelerate the discovery and development of new products.